UPDATE: Piper Sandler Starts Humacyte (HUMA) at Overweight

September 16, 2021 5:43 AM EDT
Get Alerts HUMA Hot Sheet
Price: $8.95 -1.54%

Rating Summary:
    3 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 14 | Down: 18 | New: 16
Trade Now! 
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.
(Updated - September 16, 2021 9:06 AM EDT)

Piper Sandler analyst Matt O\'Brien initiates coverage on Humacyte (NASDAQ: HUMA) with a Overweight rating and a price target of $17.00.

The analyst commented, "We are initiating coverage of HUMA with an Overweight rating and $17 PT following the completion of its SPAC merger a few weeks ago. The company manufactures a unique human acellular vessel (HAV) from donated tissue that can be used to replace autologous or synthetic vessels, which reduces the need for a second surgical site and the risk of infection. HUMA’s product is not approved at this point (likely ’23), but the combined indications it is pursuing represent markets in the tens of billions of dollars. There are risks associated with the story including regulatory approval, the price of the product ($25k each), and commercialization of the technology. With those challenges duly noted, we believe the company’s HAVs are differentiated and will find attraction in the future, which leads us to our favorable view on the name."

For an analyst ratings summary and ratings history on Humacyte click here. For more ratings news on Humacyte click here.

Shares of Humacyte closed at $13.97 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst Comments, New Coverage

Related Entities

Definitive Agreement, SPAC